Skip to main content
SpringerLink
Log in

Brinzolamide/Brimonidine: A Review of Its Use in Patients with Open-Angle Glaucoma or Ocular Hypertension

  • Adis Drug Evaluation
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Brinzolamide 1 %/brimonidine 0.2 % ophthalmic suspension (Simbrinza®) is a fixed-combination of a carbonic anhydrase inhibitor and an α2-adrenergic receptor agonist that is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension in both the USA and EU (with the EU indication restricted to patients for whom monotherapy provides insufficient IOP reduction). In phase III randomized trials, both three-times-daily and twice-daily administration of brinzolamide/brimonidine provided significantly greater IOP-lowering efficacy over 3–6 months than either of its individual components alone, and twice-daily brinzolamide/brimonidine was noninferior to concomitant administration of brinzolamide plus brimonidine over 6 months in this regard. Brinzolamide/brimonidine was generally well tolerated, with a tolerability profile that was consistent with its individual components and with no unexpected safety findings. Therefore, brinzolamide/brimonidine is an effective treatment option for patients with open-angle glaucoma or ocular hypertension, providing a convenient alternative for those patients who require multiple IOP-lowering medications. Brinzolamide/brimonidine is the first available fixed-combination that does not contain timolol, and maybe particularly suited to patients with comorbidities that restrict treatment with β-adrenergic receptor antagonists.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Casson RJ, Chidlow G, Wood JP, et al. Definition of glaucoma: clinical and experimental concepts. Clin Exp Ophthalmol. 2012;40(4):341–9.

    Article  Google Scholar 

  2. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901–11.

    Article  CAS  PubMed  Google Scholar 

  3. Nguyen QH. Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. Patient Prefer Adherence. 2014;8:853–64.

    Article  PubMed Central  PubMed  Google Scholar 

  4. European Glaucoma Society. Terminology and guidelines for glaucoma (4th edition). 2014. http://www.eugs.org. Accessed 13 Feb 2015.

  5. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701–13.

    Article  PubMed  Google Scholar 

  6. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–90.

    Article  PubMed  Google Scholar 

  7. American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern® guidelines. Primary open-angle glaucoma. 2010. http://www.aao.org/ppp. Accessed 13 Feb 2015.

  8. Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1–9.

    PubMed Central  PubMed  Google Scholar 

  9. Schwartz GF, Burk C, Bennett T, et al. Adherence and persistence with glaucoma therapy: brimonidine/timolol versus dorzolamide/timolol and various two-bottle combinations. J Clin Exp Ophthalmol. 2012;3(8). doi:10.4172/2155-9570.1000248.

  10. Roughead EE, Kalisch LM, Pratt NL, et al. Managing glaucoma in those with co-morbidity: not as easy as it seems. Ophthalmic Epidemiol. 2012;19(2):74–82.

    Article  PubMed  Google Scholar 

  11. Alcon Laboratories Inc. Simbrinza™ (brinzolamide/brimonidine tartrate ophthalmic suspension) 1 %/0.2 %: US prescribing information. 2013. http://www.fda.gov. Accessed 13 Feb 2015.

  12. Alcon Laboratories (UK) Ltd. Simbrinza 10 mg/mL + 2 mg/mL eye drops, suspension: EU summary of product characteristics. 2014. http://www.ema.europa.eu. Accessed 13 Feb 2015.

  13. DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol. 2000;44(Suppl 2):S119–29.

    Article  PubMed  Google Scholar 

  14. Cvetkovic R, Perry C. Brinzolamide. Drugs Aging. 2003;20(12):919–47.

    Article  CAS  PubMed  Google Scholar 

  15. Iester M. Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension. Clin Ophthalmol. 2008;2(3):517–23.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Adkins J, Balfour J. Brimonidine. Drugs Aging. 1998;12(3):225–41.

    Article  CAS  PubMed  Google Scholar 

  17. Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006;2(4):337–46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Ingram CJ, Brubaker RF. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. Am J Ophthalmol. 1999;128(3):292–6.

    Article  CAS  PubMed  Google Scholar 

  19. Shih GC, Calkins DJ. Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action. Expert Rev Ophthamol. 2012;7(2):161–75.

    Article  CAS  Google Scholar 

  20. Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113(12):1514–7.

    Article  CAS  PubMed  Google Scholar 

  21. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128(1):8–14.

    Article  CAS  PubMed  Google Scholar 

  22. Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2 % brimonidine. Arch Ophthalmol. 1995;113(1):77–83.

    Article  CAS  PubMed  Google Scholar 

  23. Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology. 1997;104(1):131–6.

    Article  CAS  PubMed  Google Scholar 

  24. Galanopoulos A, Goldberg I. Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension. Clin Ophthalmol. 2009;3:117–22.

    PubMed Central  CAS  PubMed  Google Scholar 

  25. Saylor M, McLoon LK, Harrison AR, et al. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol. 2009;127(4):402–6.

    Article  CAS  PubMed  Google Scholar 

  26. Katz GMD, DuBiner HMD, Samples JMD, et al. Three-month randomized trial of fixed-combination brinzolamide, 1 %, and brimonidine, 0.2 %. JAMA Ophthalmol. 2013;131(6):724–30.

  27. Nguyen QH, McMenemy MG, Realini T, et al. Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1 %/brimonidine 0.2 %. J Ocul Pharmacol Ther. 2013;29(3):290–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Aung T, Laganovska G, Hernandez Paredes TJ, et al. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology. 2014;121(12):2348–55.

    Article  PubMed  Google Scholar 

  29. Gandolfi SA, Lim J, Sanseau AC, et al. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. Adv Ther. 2014;31(12):1213–27.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Whitson JT, Realini T, Nguyen QH, et al. Six-month results from a phase III randomized trial of fixed-combination brinzolamide 1 % + brimonidine 0.2 % versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension. Clin Ophthalmol. 2013;7:1053–60.

  31. Realini T, Nguyen QH, Katz G, et al. Fixed-combination brinzolamide 1 %/brimonidine 0.2 % vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies. Eye (Lond). 2013;27(7):841–7.

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit. Sarah Greig and Emma Deeks are salaried employees of Adis/Springer.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Sarah L. Greig & Emma D. Deeks

Authors
  1. Sarah L. Greig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emma D. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah L. Greig.

Additional information

The manuscript was reviewed by: G. Laganovska, Pauls Stradins Clinical University Hospital, Riga Stradins University, Riga, Latvia; C. A. B. Webers, University Eye Clinic Maastricht, Maastricht University Medical Center, Maastricht, The Netherlands.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Greig, S.L., Deeks, E.D. Brinzolamide/Brimonidine: A Review of Its Use in Patients with Open-Angle Glaucoma or Ocular Hypertension. Drugs Aging 32, 251–260 (2015). https://doi.org/10.1007/s40266-015-0250-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-015-0250-4

Keywords

Search

Navigation